Sedative-hypnotic drugs are among the most frequently encountered agents in the settings of intentional overdose, iatrogenic toxicity, physical dependence, and challenging deprescribing scenarios. The management of these conditions demands a clinically precise understanding of drug-specific mechanisms of toxicity, the pharmacological basis of cross-tolerance and cross-dependence within the sedative-hypnotic drug class, the evidence base for withdrawal management protocols, and the nuanced considerations that govern sedative use in specialized clinical settings including the intensive care unit, palliative care, and procedural medicine.
This module synthesizes the toxicology, dependence pharmacology, and clinical management principles that span the entire sedative-hypnotic class, building on the mechanistic and pharmacokinetic foundations established in CNS-01 through CNS-03. Topics include the clinical presentation and management algorithm for sedative-hypnotic overdose; the pharmacology of cross-tolerance and physical dependence; evidence-based protocols for benzodiazepine and alcohol withdrawal; sedation in ICU and palliative care contexts; procedural sedation standards; regulatory and prescribing considerations including prescription drug monitoring program (PDMP) use; and the growing evidence base for deprescribing chronic benzodiazepines.
CLINICAL PRESENTATION: Sedative-hypnotic overdose presents as dose-dependent CNS and respiratory depression, modified by the specific agent, the dose and formulation, the presence of co-ingestants (the most clinically consequential variable), and patient-specific factors including tolerance, underlying CNS disease, and cardiopulmonary reserve.
CNS manifestations range from somnolence through obtundation, stupor, and coma. Patients may exhibit nystagmus, ataxia, dysarthria, or anterograde amnesia at lower doses. With profound CNS depression, protective airway reflexes are lost, creating aspiration risk. Hypothermia is common, mediated by hypothalamic thermoregulatory suppression.
Respiratory manifestations are the principal cause of morbidity and mortality: decreased respiratory rate and tidal volume, loss of hypercapnic respiratory drive, upper airway obstruction from pharyngeal muscle relaxation, and ultimately apnea. Pulse oximetry alone is a delayed indicator of respiratory depression, particularly in patients receiving supplemental oxygen, because SpO2 can remain deceptively normal while hypoventilation and CO2 retention progress — capnography (end-tidal CO2 monitoring) detects hypoventilation substantially earlier.1
Cardiovascular manifestations in pure benzodiazepine or Z-drug overdose are generally mild: modest hypotension and reflex tachycardia are typical. Barbiturate overdose produces more severe cardiovascular depression (direct myocardial depression, reduced systemic vascular resistance (SVR), hypotension) and may require vasopressor support. Chloral hydrate overdose carries specific risk of serious cardiac arrhythmias, including ventricular fibrillation — sensitization of the myocardium to catecholamines via a mechanism analogous to halogenated anesthetic-related arrhythmias.2
CO-INGESTANTS — THE CRITICAL AMPLIFIER: Isolated benzodiazepine overdose in a non-tolerant patient rarely causes fatal respiratory arrest; the mortality risk is dramatically amplified by co-ingestion with other CNS depressants. Opioids and alcohol are the most common co-ingestants in clinical series. Opioid co-ingestion produces additive or synergistic respiratory depression through two complementary mechanisms: benzodiazepines suppress cortical arousal and reduce the ventilatory response to hypercapnia via GABA-A receptor (GABA-A) modulation, while opioids directly depress brainstem respiratory centers via mu-opioid receptors. This combination is the pharmacological basis for the majority of prescription opioid overdose deaths — autopsy studies consistently demonstrate that benzodiazepines are co-detected in 30–75% of opioid overdose fatalities.3
MANAGEMENT ALGORITHM:
Step 1 — Airway, breathing, circulation: Supplemental oxygen and basic airway positioning are first priority. If the patient cannot protect their airway or has inadequate ventilatory effort (RR <8, increasing PCO2, SpO2 <90% on supplemental oxygen), intubation and mechanical ventilation are required. This decision must not await drug identification.
Step 2 — Targeted reversal (benzodiazepines only): Flumazenil (see CNS-01 for full discussion) may be considered in carefully selected patients: isolated benzodiazepine exposure without dependence, no known TCA or proconvulsant co-ingestion, no seizure history, and when a diagnostic or therapeutic reversal would guide management. Given the frequency of co-ingestion and the high prevalence of benzodiazepine dependence in overdose patients, flumazenil is contraindicated more often than it is indicated in emergency overdose presentations. There is no reversal agent for barbiturates, Z-drugs, chloral hydrate, propofol, or most other sedative-hypnotics.
Step 3 — Supportive care: The foundation of sedative-hypnotic overdose management. Maintain ventilation, treat hypotension (IV fluids, vasopressors as needed), correct hypothermia, and monitor for rhabdomyolysis (particularly with prolonged immobility before discovery). Aspiration pneumonitis and pneumonia are common complications.
Step 4 — Decontamination and enhanced elimination: Activated charcoal (1 g/kg, max 50 g) is appropriate if the patient presents within 1–2 hours of ingestion with intact or protected airway. For phenobarbital specifically, multi-dose activated charcoal (multiple-dose activated charcoal (MDAC): 25–50 g every 4–6 hours) significantly enhances elimination through interruption of enterohepatic recirculation and gastrointestinal dialysis — this is one of the clearest indications for MDAC in clinical toxicology.4 Urinary alkalinization with IV sodium bicarbonate (targeting urine pH 7.5–8.0) also increases renal elimination of phenobarbital by ion-trapping the ionized form in the urine; this is most useful when combined with MDAC. Hemodialysis may be considered for life-threatening phenobarbital toxicity that does not respond to supportive care.
Step 5 — Psychiatric evaluation and disposition: All patients with intentional overdose require psychiatric evaluation after medical stabilization, with attention to ongoing suicidality risk, substance use disorder assessment, and social support.
CROSS-TOLERANCE AND CROSS-DEPENDENCE: All sedative-hypnotic drugs that act at the GABA-A receptor (GABA-A) share cross-tolerance and cross-dependence. This is a fundamental pharmacological principle with major clinical implications: a patient physically dependent on alcohol will require substantially larger doses of a benzodiazepine to achieve sedation; a patient on chronic high-dose benzodiazepines will show reduced sensitivity to barbiturate effects; and during withdrawal from any one of these agents, any other GABA-A-active drug can suppress withdrawal symptoms.5
The neurobiological basis of cross-dependence is shared receptor-level neuroadaptation: chronic exposure to any GABA-A-potentiating agent produces compensatory downregulation of GABA-A receptor expression, internalization of surface receptors, altered subunit phosphorylation states, and upregulation of excitatory pathways (particularly NMDA glutamate receptors and voltage-gated calcium channels).5 When the sedative-hypnotic agent is removed, the resulting imbalance — reduced inhibitory tone and enhanced excitatory tone — produces the withdrawal syndrome regardless of which specific GABA-A-active agent was causing the dependence.
CLINICAL APPLICATIONS OF CROSS-DEPENDENCE: This pharmacological principle underlies several clinical management strategies:
Benzodiazepine taper using a long-acting agent: A patient physically dependent on a short-acting, high-potency benzodiazepine (alprazolam) is converted to an equivalent dose of a long-acting benzodiazepine (diazepam) before beginning a structured taper. The cross-dependence ensures the long-acting agent fully suppresses the withdrawal syndrome, while its prolonged half-life eliminates the inter-dose withdrawal and smooth-tapering kinetics discussed in CNS-01.
Alcohol withdrawal management with benzodiazepines: Benzodiazepines suppress alcohol withdrawal because the GABA-A receptor neuroadaptations driving alcohol withdrawal are identical to those that benzodiazepines modulate. The same neuroadaptation that creates cross-dependence between these agents also makes benzodiazepines the pharmacological treatment for alcohol withdrawal.
Phenobarbital for benzodiazepine and alcohol withdrawal: Phenobarbital's ability to suppress withdrawal from both alcohol and benzodiazepines reflects the same cross-dependence principle plus the added mechanistic advantage that phenobarbital can directly activate GABA-A channels at high concentrations, bypassing the receptor downregulation that limits benzodiazepine efficacy in severe withdrawal states.
TOLERANCE SPECTRUM: As discussed in CNS-01, tolerance develops at different rates across different drug effects. A clinically important and often underappreciated consequence is that patients who have developed profound behavioral and cognitive tolerance — appearing functionally "normal" on doses that would sedate a naive patient — still retain sufficient physical dependence to experience life-threatening withdrawal upon abrupt discontinuation. Tolerance to the lethality-protective aspects of benzodiazepines (relative to overdose) does not develop to the same degree as behavioral tolerance, which partially explains why chronic high-dose benzodiazepine users who relapse or combine their agent with opioids or alcohol face a substantially higher overdose risk than their apparent functional tolerance might suggest.
Gabapentin and pregabalin — structurally related to GABA but acting primarily through binding to the α2δ subunit of voltage-gated calcium channels rather than GABA-A receptors directly — have emerged as a significant category of misused sedative agents with important clinical implications for the sedative-hypnotic class. Both produce CNS depression, euphoria (particularly pregabalin), anxiolysis, and dose-dependent sedation, and their misuse has increased substantially in parallel with opioid prescribing restrictions, as patients with substance use disorders have transitioned to or added gabapentinoids as more readily available alternatives.5 Although gabapentinoids do not produce classical cross-tolerance with benzodiazepines through GABA-A receptor-level mechanisms, they modulate neuronal excitability in ways that interact with the GABAergic and glutamatergic adaptations underlying sedative-hypnotic dependence — which is why both gabapentin and pregabalin have clinical utility as adjuncts in benzodiazepine and alcohol withdrawal management.
Withdrawal from chronic high-dose gabapentinoids can produce a syndrome resembling benzodiazepine withdrawal, including anxiety, insomnia, diaphoresis, tremor, and seizures, though the clinical literature on gabapentinoid withdrawal is less mature than for classical sedative-hypnotics. Prescribers of benzodiazepines and other sedatives should routinely assess concurrent gabapentinoid use: the combination produces additive CNS and respiratory depression that amplifies overdose risk, a pharmacodynamic interaction increasingly recognized in overdose mortality surveillance. The 2019 FDA safety communication on serious respiratory depression with gabapentinoids explicitly identifies concurrent benzodiazepine and opioid use as key risk factors. Pregabalin is Schedule V in the US; gabapentin remains unscheduled federally but has been scheduled in several states due to documented misuse. Prescription Drug Monitoring Program (PDMP) programs in states where gabapentinoids are scheduled provide an additional tool for identifying patients receiving concurrent CNS depressant prescriptions from multiple providers.
ASSESSMENT BEFORE TAPERING: Before initiating a benzodiazepine taper, clinicians must assess: the agent, dose, and duration of use; the clinical indication (is the underlying condition still present and treatable by non-benzodiazepine means?); the degree of physical dependence (inter-dose symptoms, prior withdrawal history, dose escalation history); comorbid psychiatric conditions and substance use disorders; and the patient's motivation, understanding, and social support for the taper process.6
EQUIVALENCY TABLE — DIAZEPAM EQUIVALENTS: The following approximate equivalencies are used for conversion to diazepam for taper planning. Individual variation is significant, and these should serve as a starting framework, not rigid prescriptions:
Diazepam 5 mg ≈ Lorazepam 0.5 mg ≈ Alprazolam 0.25–0.5 mg ≈ Clonazepam 0.25–0.5 mg ≈ Chlordiazepoxide 12.5 mg ≈ Oxazepam 10–15 mg ≈ Temazepam 10 mg ≈ Triazolam 0.125 mg
Note that alprazolam equivalency is sometimes cited as 0.5 mg alprazolam per 5 mg diazepam, but many clinicians use a more conservative 0.25 mg alprazolam per 5 mg diazepam given alprazolam's high potency and rapid receptor binding kinetics. The conservative estimate is appropriate when initiating the taper in high-dose users.6
TAPER RATE AND DURATION: Evidence supports a rate of no faster than 5–10% of current dose per week. In practice, many patients manage well at 10%/week during the early stages of the taper when the dose is high, but require slower reductions (5% or less per 2 weeks) as the dose decreases and each incremental reduction represents a larger proportional change in receptor occupancy. The "Ashton manual" framework — converting to diazepam and reducing by approximately 0.5–2 mg diazepam equivalents every 2 weeks — provides a practical clinical starting point, with the expectation of taper duration of months to years for patients on long-term high-dose therapy.6
PHARMACOLOGICAL ADJUNCTS TO BENZODIAZEPINE TAPER: Several agents are used as adjuncts to manage withdrawal symptoms during the taper, though none is a substitute for a properly structured taper:
Carbamazepine: Evidence from randomized trials supports carbamazepine (600–800 mg/day in divided doses) as an effective adjunct to reduce withdrawal symptom severity and seizure risk during benzodiazepine taper. Its mechanisms include sodium channel blockade and modulation of kindling phenomena that contribute to withdrawal seizure risk.7
Pregabalin and gabapentin: Both have been used as adjuncts in benzodiazepine withdrawal, leveraging their α2δ calcium channel subunit modulation to reduce neuronal hyperexcitability. Evidence is less robust than for carbamazepine but clinical use is widespread, particularly pregabalin (150–450 mg/day).
Beta-blockers and clonidine: These agents address the sympathomimetic symptoms of withdrawal (tachycardia, hypertension, diaphoresis) but do not prevent seizures or delirium and should not be used as monotherapy in patients at risk for severe withdrawal.
SSRIs/SNRIs: Initiation of SSRI or SNRI therapy during the taper addresses the underlying anxiety disorder that frequently drives benzodiazepine use, supporting the taper by providing non-addictive anxiolytic pharmacotherapy. This is considered standard practice when the benzodiazepine was initiated for an anxiety disorder.
PATHOPHYSIOLOGY REVIEW: Chronic alcohol use leads to compensatory neuroadaptation at GABA-A receptors (GABA-A) (downregulation, reduced sensitivity) and NMDA glutamate receptors (upregulation, increased expression and sensitivity). Upon alcohol cessation, the resulting excitatory-inhibitory imbalance drives the alcohol withdrawal syndrome — a clinical spectrum ranging from mild autonomic hyperactivity to life-threatening seizures and delirium tremens (DT).8
CLINICAL TIMELINE OF ALCOHOL WITHDRAWAL:
6–24 hours: Tremor, anxiety, tachycardia, hypertension, diaphoresis, nausea. Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) scores typically mild to moderate.
24–48 hours: Withdrawal seizures — typically single generalized tonic-clonic events, though may be multiple; status epilepticus occurs in approximately 3% of withdrawing patients. Peak seizure risk is in this window.
48–96 hours: Delirium tremens — confusion, agitation, hallucinations (visual most characteristic), autonomic instability, hyperthermia. DT carries a mortality rate of 5–15% even with treatment; untreated mortality has historically exceeded 35%.8 DT is a medical emergency.
CIWA-Ar PROTOCOL: The Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) is a validated 10-item scoring instrument assessing nausea/vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation. Scores of 8–9 or less suggest mild withdrawal; 10–14 moderate; ≥15 severe. Symptom-triggered dosing — administering benzodiazepines only when CIWA-Ar scores exceed a threshold (typically 8–10) — has been shown in multiple randomized trials to reduce total benzodiazepine consumption by 60–70%, shorten treatment duration, and reduce complications compared to fixed-schedule dosing, without increasing seizure risk in patients with intact cognitive function who can cooperate with scoring.8
BENZODIAZEPINE SELECTION FOR ALCOHOL WITHDRAWAL:
Long-acting agents (diazepam, chlordiazepoxide): Preferred in medically stable patients without hepatic disease. Self-tapering pharmacokinetics reduce the complexity and risk of withdrawal management. Typical diazepam loading approach: 10–20 mg every 1–2 hours until the patient is calm (CIWA-Ar <8), with maintenance dosing as needed. Front-loading strategies (higher initial doses to rapidly suppress the withdrawal) may reduce the total medication required and shorten the treatment course.
Short-to-intermediate acting agents without active metabolites (lorazepam, oxazepam): Reserved for patients with hepatic disease, elderly patients, or medically complex patients where accumulation of long-acting agents is dangerous. More frequent dosing and closer monitoring are required without the self-tapering advantage.
PHENOBARBITAL LOADING FOR ALCOHOL WITHDRAWAL: The resurgent use of phenobarbital loading in alcohol withdrawal syndrome (AWS) management reflects important mechanistic advantages over benzodiazepine-only protocols, particularly in patients with severe withdrawal or patients in whom benzodiazepines have proven insufficient. A prospective randomized trial and multiple observational studies support the efficacy of phenobarbital 10–15 mg/kg IV over 30–60 minutes for symptom reduction and prevention of complications.9
The pharmacological rationale for phenobarbital's superiority in severe withdrawal is threefold: (1) at concentrations achieved with loading doses, phenobarbital directly activates GABA-A chloride channels independently of GABA, bypassing the receptor downregulation that limits benzodiazepine efficacy in severe withdrawal; (2) phenobarbital inhibits AMPA glutamate receptors, directly attenuating the excitatory hyperactivity that is the other limb of withdrawal pathophysiology; and (3) phenobarbital's long half-life (80–120 hours) provides sustained coverage without the pharmacokinetic instability of shorter-acting agents.9 Current evidence has shifted several emergency medicine and critical care programs toward phenobarbital-first or phenobarbital-adjunctive protocols for moderate-to-severe AWS, with benzodiazepines as adjuncts for breakthrough symptoms.
ADJUNCTIVE AGENTS IN ALCOHOL WITHDRAWAL: Thiamine (vitamin B1) supplementation (500 mg IV three times daily for at least 3 days) is mandatory in patients presenting with alcohol use disorder to prevent Wernicke encephalopathy — a potentially devastating complication of thiamine deficiency. Administration of glucose before thiamine in thiamine-depleted patients can precipitate Wernicke encephalopathy; thiamine must precede or accompany glucose administration. Dexmedetomidine as an adjunct in ICU-level AWS management has evidence supporting reduction of benzodiazepine/phenobarbital requirements through its sympatholytic effects, but it does not prevent seizures or delirium and should not be used as a primary withdrawal management agent. Magnesium repletion (IV magnesium sulfate) is appropriate in patients with documented hypomagnesemia, which is common in chronic alcohol use disorder and which independently lowers the seizure threshold.
ICU SEDATION PROTOCOLS: Contemporary ICU sedation has been transformed by the evidence demonstrating that deep continuous sedation (previously the default) is independently associated with worse outcomes, including prolonged mechanical ventilation, ICU-acquired weakness, cognitive impairment, and post-traumatic stress disorder.10 The current PADIS (Pain, Agitation/Sedation, Delirium, Immobility, Sleep) guidelines from the Society of Critical Care Medicine endorse: analgesia-first sedation (treat pain before adding sedatives); light sedation target (Richmond Agitation-Sedation Scale (RASS) 0 to -2) as default for most mechanically ventilated patients; daily spontaneous awakening trials (SATs) combined with spontaneous breathing trials (SBTs); and avoidance of benzodiazepine infusions in preference for propofol or dexmedetomidine for most ICU sedation needs.10
Benzodiazepine infusions (midazolam) are associated with prolonged mechanical ventilation, delirium, and drug accumulation in ICU patients compared to propofol and dexmedetomidine, and are now reserved for specific situations: patients who require deep sedation for clinical reasons (refractory status epilepticus, severe acute respiratory distress syndrome (ARDS) requiring neuromuscular blockade, management of alcohol withdrawal in patients with hemodynamic instability precluding dexmedetomidine). The MENDS2 trial (dexmedetomidine vs lorazepam in ICU sedation) and Sleep-Promoting, Sedation Long-Term Evaluation and Analgesia Practice trial (SLEAP) trials have provided robust evidence favoring dexmedetomidine over other sedatives for specific ICU populations — particularly those at high risk for delirium.10
PALLIATIVE CARE SEDATION: Sedation in the context of palliative care refers to the intentional use of sedating medications to relieve refractory, intolerable symptoms in patients near the end of life when other management strategies have been exhausted.11 The European Association for Palliative Care framework distinguishes between proportionate palliative sedation — titrated to the minimum depth that provides symptom relief, with preserved patient interaction when possible — and continuous deep sedation until death, reserved for patients with hours-to-days prognosis whose symptoms cannot be controlled at lighter sedation levels. The ethical principle of double effect — that an action with both beneficial and potentially harmful consequences is permissible when the intent is benefit and harm is proportionate and not directly intended — distinguishes palliative sedation from euthanasia. Evidence from prospective studies suggests that appropriately titrated palliative sedation does not hasten death in most patients. Refractory symptoms most commonly prompting palliative sedation include dyspnea, agitated delirium, refractory pain, and existential suffering.
Midazolam remains the most commonly used agent for palliative sedation due to its rapid titratability, availability in subcutaneous formulations (critical in patients without IV access), and wide clinical familiarity. For continuous subcutaneous infusion (CSCI), midazolam is typically initiated at 10–30 mg/24 hours with breakthrough doses of 2.5–5 mg as needed; doses may escalate to 60–120 mg/24 hours or higher in refractory cases. Lorazepam (subcutaneous or IV, 0.5–4 mg every 4 hours or by CSCI) provides an alternative with less titratability. Phenobarbital by subcutaneous infusion (starting at 200–400 mg/24 hours, escalating as needed) is the agent of choice for refractory terminal agitation and intractable seizures, particularly when deep sustained sedation is required and midazolam has been insufficient. Goals of care documentation, patient or surrogate consent when capacity exists, interdisciplinary team agreement, and clearly articulated treatment intent are non-negotiable elements of palliative sedation practice.
PROCEDURAL SEDATION — STANDARDS AND REQUIREMENTS: Safe procedural sedation outside the operating room requires systematic pre-procedure assessment and adherence to established standards. Pre-procedure assessment must include: American Society of Anesthesiologists (ASA) physical status classification; airway assessment (Mallampati class, mouth opening, thyromental distance, neck mobility) to identify potential difficult airway; nil per os — nothing by mouth (NPO) status per ASA guidelines (2 hours for clear liquids, 6 hours for light meals, 8 hours for fatty meals — subject to modification in urgent situations); identification of comorbidities increasing sedation risk including obstructive sleep apnea (OSA), severe COPD, morbid obesity, and significant cardiovascular disease; and current medications, allergies, and prior adverse reactions to sedation. Informed consent must explicitly address the planned sedation depth, risks including respiratory depression and aspiration, and possibility of conversion to deeper sedation or general anesthesia. Minimum monitoring for moderate sedation includes continuous pulse oximetry, cardiac monitoring, non-invasive blood pressure at maximum 5-minute intervals, and continuous clinical observation of ventilation. For deep sedation, capnography is required by most institutional standards, detecting hypoventilation substantially earlier than pulse oximetry particularly in patients receiving supplemental oxygen. A dedicated monitoring provider separate from the proceduralist is mandatory for anything beyond minimal sedation. Flumazenil and naloxone must be immediately available. Post-procedure recovery must document return to pre-sedation baseline using a validated scoring tool before discharge, with explicit criteria for unescorted discharge including time minimum, vital sign stability, ambulation ability, and presence of a responsible adult escort.12
Chronic benzodiazepine use during pregnancy, particularly in the third trimester, can produce neonatal abstinence syndrome (NAS) reflecting the withdrawal physiology that develops in the neonate after delivery and placental drug transfer ceases.16 The pharmacological basis mirrors adult benzodiazepine withdrawal: fetal exposure produces GABA-A receptor (GABA-A) downregulation and compensatory upregulation of excitatory pathways; at delivery, abrupt cessation of maternal drug transfer unmasks the resulting neurological hyperexcitability. Neonatal benzodiazepine-associated neonatal abstinence syndrome (BZD-NAS) typically presents within 24–72 hours of birth — earlier than opioid NAS, reflecting shorter benzodiazepine half-lives in the fetal compartment — and manifests as irritability, high-pitched crying, tremulousness, hypotonia alternating with hypertonia, feeding difficulties, poor sleep consolidation, and in severe cases, seizures. Management is primarily supportive, including minimizing stimulation through reduced lighting and limited handling, swaddling, and optimizing feeding. When pharmacological treatment is required, phenobarbital is the agent of choice for BZD-NAS, as its GABA-A potentiating and direct channel-activating properties address the underlying withdrawal physiology and its long half-life provides smooth self-tapering coverage. Clinicians managing pregnant patients on benzodiazepines should plan delivery at facilities equipped for neonatal monitoring, communicate in-utero exposure to the neonatal team in advance, and avoid abrupt benzodiazepine discontinuation near term — acute maternal withdrawal may be more harmful than controlled neonatal NAS management after birth.
SCHEDULING AND PRESCRIPTION DRUG MONITORING PROGRAM (PDMP) REQUIREMENTS: Benzodiazepines, Z-drugs (zolpidem, zaleplon, eszopiclone), and orexin receptor antagonists (suvorexant, lemborexant) are all Schedule IV controlled substances in the US. Prescribers are required by law in the vast majority of states to check the PDMP before prescribing any scheduled substance to a new patient, and most states mandate periodic PDMP review for established patients on chronic scheduled medications.13 The PDMP serves as the primary tool for detecting concurrent prescriptions from multiple providers (doctor shopping), identifying patients receiving dangerous co-prescriptions (particularly opioids plus benzodiazepines), and informing risk-stratification before prescribing.
THE OPIOID-BENZODIAZEPINE CO-PRESCRIPTION EPIDEMIC: The FDA issued a black box warning in 2016 for all opioid analgesics and all benzodiazepines requiring labeling about the risk of combined use, citing a three-to-four-fold increase in overdose mortality when both drug classes are co-prescribed.3 Despite this warning, population-level co-prescribing rates remain clinically problematic. For any patient on chronic opioid therapy, a thorough review of sedative-hypnotic co-prescriptions is mandatory; when co-prescribing cannot be avoided, prescribers must engage in explicit risk counseling, consider naloxone co-prescription, and maintain the lowest effective doses of both agents.
INFORMED CONSENT ELEMENTS FOR CHRONIC BENZODIAZEPINE PRESCRIBING: Good clinical practice and emerging medicolegal standards support formal documentation of the following when initiating (or continuing) chronic benzodiazepine therapy: the indication; the planned duration and review schedule; discussion of tolerance, dependence, and withdrawal; discussion of cognitive, psychomotor, and fall risks; discussion of interaction with alcohol and opioids; discussion of alternative treatments; and an explicit statement that the goal is the lowest effective dose for the shortest necessary duration.
DEPRESCRIBING EVIDENCE — CHRONIC BENZODIAZEPINES: A growing evidence base from randomized controlled trials and systematic reviews supports structured deprescribing of benzodiazepines, particularly in elderly patients and primary care populations.6 Key findings:
Success rates: Structured taper programs achieve successful discontinuation in 40–80% of long-term benzodiazepine users in randomized trials. Rates are highest when the taper is combined with psychological support (CBT, motivational interviewing).
Brief physician advice: Even a brief structured letter or conversation from the prescribing physician explicitly recommending benzodiazepine reduction has been shown in randomized trials to produce significant reductions in benzodiazepine use at 6 months compared to usual care. This low-effort intervention should be routine in any patient on chronic benzodiazepine therapy.14
Digital and telehealth deprescribing programs: Evidence for digital CBT platforms and telephone-based tapering support programs is emerging, with particular relevance in primary care settings where access to in-person behavioral health support is limited — relevant to the rural medicine context where the practical barriers to deprescribing include not just clinical but also logistical challenges for patients.
Functional outcomes: Patients who successfully taper off benzodiazepines consistently demonstrate improvements in cognitive function, sleep quality, psychomotor performance, and quality of life — outcomes that can be used motivationally with patients who are ambivalent about discontinuation.14 Communicating these anticipated benefits is an important component of the deprescribing conversation.
PRESCRIBING FRAMEWORK — A PRACTICAL APPROACH:
For any patient being considered for a new benzodiazepine or Z-drug prescription, a structured approach includes: (1) confirming that non-pharmacological treatment has been considered or offered; (2) PDMP review; (3) identifying concurrent CNS depressants (opioids, muscle relaxants, gabapentinoids, alcohol use); (4) selecting the most appropriate agent for the indication (see prior modules for indication-specific guidance); (5) using the lowest effective dose for the intended duration; (6) for chronic prescribing, documenting a clear indication, treatment duration, and monitoring plan; and (7) scheduling a follow-up specifically to reassess the continued need.
The DSM-5 categorizes problematic benzodiazepine use under Sedative, Hypnotic, or Anxiolytic Use Disorder, defined as a problematic pattern of use leading to clinically significant impairment or distress, manifested by two or more of eleven criteria within a 12-month period.17 The eleven criteria span four domains. Impaired control: taking larger amounts or for longer than intended; persistent desire or unsuccessful efforts to cut down or control use; spending substantial time obtaining, using, or recovering from the substance; craving or a strong urge to use. Social impairment: failure to fulfill major role obligations at work, school, or home; continued use despite persistent social or interpersonal problems caused or exacerbated by the substance; giving up or reducing important social, occupational, or recreational activities. Risky use: recurrent use in situations where it is physically hazardous; continued use despite knowledge of a persistent physical or psychological problem caused or exacerbated by the substance. Pharmacological criteria: tolerance (requiring markedly increased amounts for the desired effect, or markedly diminished effect with continued use of the same amount); withdrawal (the characteristic withdrawal syndrome, or taking the substance to relieve or avoid withdrawal symptoms). Severity is specified as mild (2–3 criteria), moderate (4–5 criteria), or severe (6 or more criteria).
A critical clinical distinction is that tolerance and withdrawal alone, when occurring solely in the context of medically supervised therapeutic use and in the absence of the other criteria, do not constitute a use disorder under DSM-5 — this distinction is frequently misunderstood by patients and occasionally by clinicians, and failure to explain it clearly can damage therapeutic relationships and create barriers to appropriate prescribing. The prevalence of benzodiazepine use disorder among patients prescribed benzodiazepines long-term is estimated at 10–44% depending on diagnostic criteria and population studied, with substantially higher rates in patients with comorbid opioid use disorder, alcohol use disorder, or other substance use disorders.17 Recognition of use disorder requires moving beyond dose and duration to assess the full behavioral and functional criterion picture. Management extends beyond structured tapering to include motivational interviewing, cognitive-behavioral therapy for substance use, peer support, and in severe cases, referral to structured addiction treatment programs with specific expertise in sedative-hypnotic dependence — a treatment category that is underserved relative to opioid use disorder infrastructure in most health systems.
Stolbach A, Hoffman RS. Opioid and sedative-hypnotic toxidrome. In: Tintinalli JE, et al., eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide. 9th ed. McGraw-Hill; 2020.
Park BK, Coleman JW, Howe AM. Interaction of chloral hydrate with the cardiac sodium channel. J Pharmacol Exp Ther. 1985;234(2):342–349.
Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760.
doi:10.1136/bmj.j760Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. J Toxicol Clin Toxicol. 2004;42(1):1–26.
doi:10.1081/CLT-120028740Lader M. Dependence and withdrawal: comparison of the benzodiazepines and selective serotonin re-uptake inhibitors. Addiction. 2012;107(5):909–910.
doi:10.1111/j.1360-0443.2011.03629.xAshton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005;18(3):249–255.
doi:10.1097/01.yco.0000165594.60434.84Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Arch Gen Psychiatry. 1991;48(5):448–452.
doi:10.1001/archpsyc.1991.01810290060011Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA. 1997;278(2):144–151.
doi:10.1001/jama.1997.03550020076042Tidwell WP, Thomas TL, Pouliot JD, Canonico AE, Webber AJ. Treatment of alcohol withdrawal syndrome: phenobarbital vs CIWA-Ar protocol. Am J Crit Care. 2018;27(6):454–460.
doi:10.4037/ajcc2018745Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825–e873.
doi:10.1097/CCM.0000000000003299Cherny NI, Radbruch L; Board of the European Association for Palliative Care. European Association for Palliative Care recommended framework for the use of sedation in palliative care. Palliat Med. 2009;23(7):581–593.
doi:10.1177/0269216309107024American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002;96(4):1004–1017.
doi:10.1097/00000542-200204000-00031Griggs CA, Weiner SG, Feldman JA. Prescription drug monitoring programs: examining limitations and future approaches. West J Emerg Med. 2015;16(1):67–70.
doi:10.5811/westjem.2014.10.24197Mugunthan K, McGuire T, Glasziou P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pract. 2011;61(590):e573–e578.
doi:10.3399/bjgp11X593063American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081.
doi:10.1111/jgs.18372Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540–e560.
doi:10.1542/peds.2011-3212American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013. Sedative, Hypnotic, or Anxiolytic Use Disorder, pp 550–556.